Cardiovascular Risk of Essential Hypertension: Influence of Class, Number, and Treatment-Time Regimen of Hypertension Medications
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
A number of observational studies have found that treated hypertensive patients, even those with controlled clinic blood pressure (BP), might have poorer prognosis than untreated hypertensives. Different trials have also shown that relatively low cardiovascular disease (CVD) risk cannot be achieved in high-risk hypertensive patients, leading to the belief they have a "residual CVD risk" that cannot be attenuated by conventional treatment. All these conclusions disregard the facts that the correlation between BP level and CVD risk is stronger for ambulatory than clinic BP and that the BP-lowering efficacy and effects on the 24-h BP pattern of different classes of hypertension medications exhibit statistically and clinically significant treatment-time (morning versus evening) differences. Accordingly, we evaluated the potential differential administration-time-dependent effects on CVD risk of the various classes of hypertension medications and the number of them used for therapy in the MAPEC (Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares, i.e., Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular Events) study, a prospective, open-label, blinded-endpoint trial on 2156 hypertensive patients (1044 men/1112 women), 55.6 ± 13.6 (mean ± SD) yrs of age, randomized to ingest all prescribed once-a-day hypertension medications upon awakening or the entire daily dose of ≥1 of them at bedtime. Ambulatory BP was measured for 48 h at baseline, and again annually or more frequently (quarterly) when adjustment of treatment was necessary to achieve ambulatory, i.e., awake and asleep, BP control. CVD risk according to the number and classes of medications used at the final evaluation was calculated by comparison with that of 734 normotensive subjects who were identically followed and remained untreated. After a median follow-up of 5.6 yrs, CVD risk of hypertensive patients randomized to ingest all medications upon awakening was progressively higher with increase in the number of medications (adjusted hazard ratio [HR]: 1.75, 2.26, 3.02, and 4.18 in patients treated with 1, 2, 3, and ≥4 medications daily, respectively; p < .001 compared with normotensive subjects). CVD risk was markedly lower in patients ingesting ≥1 medications at bedtime (HR: .35, 1.45, .94, and 2.28 with 1, 2, 3, and ≥4 medications daily, respectively), and even lower in patients ingesting all medications at bedtime (HR: .35, .39, .87, and .79 with 1, 2, 3, and ≥4 medications daily, respectively). Patients ingesting ≥1 medications at bedtime evidenced significantly lower CVD risk than those ingesting all medications upon awakening, independent of class. Greater benefits were observed for bedtime compared with awakening treatment with angiotensin-II receptor blockers (ARBs) (HR: .29 [95% confidence interval, CI .17-.51]; p < .001) and calcium channel blockers (HR: .46 [95% CI: .31-.69]; p < .001). CVD risk was similar for all six classes of tested hypertension medications in patients randomized to ingest all of them upon awakening. Among patients randomized to ingest ≥1 medications at bedtime, however, ARBs were associated with significantly lower HR of CVD events than ingestion of any other class of medication also at bedtime (p < .017). We document significantly reduced CVD risk among hypertensive patients ingesting medications at bedtime, independent of the number of hypertension medications required to achieve proper ambulatory BP control. These findings challenge the current belief of "residual CVD risk," as a bedtime-treatment regimen of current hypertension medications, even in risk-high patients, can reduce such risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643 · cited 6×
“…current international guidelines indicate that treated hypertensive patients will always present higher CVD risk, the so-called “residual risk,” than untreated ones, no matter how intense the treatment might be or how low the clinic BP is reduced (Chobanian et al., 2003; Mancia et al., 2007, 2009).”
BackgroundInfluentialGrundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Cardiology in Review · doi:10.1097/01.crd.0000380842.14048.7e · Cited by 1,600
Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated Hypertension
Clement, D. L., De Buyzere, M. L., De Bacquer, D. A., de Leeuw, P. W., Duprez, D. A., Fagard, R. H., Gheeraert, P. J., Missault, L. H., Braun, J. J., Six, R. O., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022273 · Cited by 1,085 · cited 2×
“It is now well established that the correlation between BP level and target organ damage, CVD risk, and long-term prognosis is stronger for ambulatory than clinic BP (Clement et al., 2003; Eguchi et al., 2008; Hermida et al., 2011b, 2013a, 2013d; Perloff et al., 1983; Salles et al., 2008; Verdecchia et al., 1994) and…”
BackgroundHermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2010) · Chronobiology International · doi:10.3109/07420528.2010.510230 · Cited by 608 · cited 11×
“…efficacy, duration of action, safety, and/or effects upon the 24-h BP pattern of six different classes of hypertension medications and their combinations have been reported (Hermida & Smolensky, 2004; Hermida et al., 2005a, 2007a, 2010c, 2011a, 2011e, 2013b; Smolensky et al., 2010, 2012).”
BackgroundInfluentialSelf-citationPrognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension
Salles, G. F., Cardoso, C. R. L., & Muxfeldt, E. S. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.21.2340 · Cited by 293
Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2011) · Diabetes Care · doi:10.2337/dc11-0297 · Cited by 213 · cited 15×
“…ingested at bedtime might be related to their significantly greater reduction of the asleep SBP and DBP means plus increase of the sleep-time relative BP decline towards the more normal dipper pattern associated with lower CVD risk than when ingested upon awakening (Hermida et al., 2011b, 2013a).”
BackgroundInfluentialSelf-citationHermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701127 · Cited by 203
Self-citationHermida, R. C., Ayala, D. E., Fernandez, J. R., Portaluppi, F., Fabbian, F., & Smolensky, M. H. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2010.217 · Cited by 159 · cited 15×
“…ingested at bedtime might be related to their significantly greater reduction of the asleep SBP and DBP means plus increase of the sleep-time relative BP decline towards the more normal dipper pattern associated with lower CVD risk than when ingested upon awakening (Hermida et al., 2011b, 2013a).”
BackgroundInfluentialSelf-citationAyala, D. E., Hermida, R. C., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701455 · Cited by 87 · cited 7×
“, 2010) and has been demonstrated to be of clinical importance; the progressive decrease of asleep BP, best achieved with ≥1 hypertension medications at bedtime, is significantly associated with increased event-free CVD survival (Ayala et al., 2013; Hermida et al., 2010d, 2011b, 2011c, 2011d, 2012a, 2013a).”
BackgroundInfluentialSelf-citation
Cited by
Circadian mechanisms of 24-hour blood pressure regulation and patterning
Smolensky, M. H., Hermida, R. C., & Portaluppi, F. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.02.003 · Cited by 237
Self-citationHermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013) · Chronobiology International · doi:10.3109/07420528.2012.701127 · Cited by 203
Self-citationChronotherapy With Low-Dose Aspirin for Prevention of Complications in Pregnancy
Ayala, D. E., Ucieda, R., & Hermida, R. C. (2013) · Chronobiology International · doi:10.3109/07420528.2012.717455 · Cited by 203
“…recently documented that the progressive reduction in asleep BP mean, a novel therapeutic target best achieved with bedtime hypertension therapy (Hermida et al., 2011a, 2013b; Portaluppi & Smolensky, 2010; Smolensky et al., 2010), is the most significant predictor of cardiovascular event-free…”
BackgroundInfluentialSelf-citationSmolensky, M. H., Hermida, R. C., Reinberg, A., Sackett-Lundeen, L., & Portaluppi, F. (2016) · Chronobiology International · doi:10.1080/07420528.2016.1184678 · Cited by 197
Self-citationFabbian, F., Smolensky, M. H., Tiseo, R., Pala, M., Manfredini, R., & Portaluppi, F. (2013) · Chronobiology International · doi:10.3109/07420528.2012.715872 · Cited by 147
Metadata
- Authors
- Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R.
- Venue
- Chronobiology International
- Publisher
- Informa UK Limited
- Published
- 2012-10-25
- Volume
- 30
- Issue
- 1-2
- Pages
- 315-327
- ISSN
- 0742-0528 (ISSN-L)
- 1525-6073
- OpenAlex
- W2037073481
- Cited by
- 68
- References
- 9
- FWCI
- 7.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiovascular Risk of Essential Hypertension: Influence of Class, Number, and Treatment-Time Regimen of Hypertension Medications. https://app.cochat.ai/papers/10.3109/07420528.2012.701534
- The paper
- Hermida, R. C., Ayala, D. E., Mojón, A., & Fernández, J. R. (2013). Cardiovascular Risk of Essential Hypertension: Influence of Class, Number, and Treatment-Time Regimen of Hypertension Medications. Chronobiology International. https://doi.org/10.3109/07420528.2012.701534
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.